Genenta Science S.p.A. Unsponsored ADR GNTA
0.69
0.02
2.99%
as of 25 Sep
- Market cap
- $32.4M
- P/E
- —
Follow GNTA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 8.29 | 7.09 | 34.15 | 14.53 | 12.25 | 6.89 | 14.16 |
Net Debt/EBITDA |
— | 4.37 | 2.77 | 6.55 | 2.70 | 1.61 | 1.30 | 3.12 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.84% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.54 | 1.08 | 1.26 | 0.88 | 0.96 | 0.70 | 1.05 |
Capex/Depreciation |
— | — | (10.82) | (1.84) | (4.38) | (0.32) | (0.10) | (0.27) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (25.93%) | (33.21%) | (20.67%) | (22.68%) | (45.90%) | (54.13%) | (38.65%) | |
| — | (42.95%) | (29.06%) | (19.43%) | (21.63%) | (42.43%) | (47.95%) | (28.35%) | |
ROIC |
— | 0.00% | 0.00% | (219.27%) | (513.85%) | (442.67%) | 0.00% | (318.86%) |
Return on Tangible Assets |
— | (25.31%) | (39.33%) | (14.69%) | (28.59%) | (59.40%) | (71.78%) | (23.42%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.15) | (0.48) | (0.55) | (0.43) | (0.67) | (0.37) | (0.39) |
Cash per Share |
— | 1.25 | 1.22 | 2.92 | 1.72 | 1.12 | 0.75 | 1.62 |
Shareholders Equity per Share |
— | 1.17 | 1.19 | 3.05 | 1.80 | 1.21 | 0.74 | 1.25 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 1.17 | 1.19 | 3.05 | 1.80 | 1.21 | 0.74 | 1.25 |
Free Cash Flow |
— | (2.79) | (6.93) | (8.24) | (7.84) | (12.14) | (6.76) | (7.78) |
Working Capital |
— | 20.33 | 16.22 | 44.51 | 31.12 | 21.13 | 13.39 | 31.52 |
Capital Expenditures |
— | — | (0.02) | (0.01) | (0.03) | (0.01) | 0.00 | (0.01) |
Net Current Asset Value |
— | 20.32 | 16.20 | 44.48 | 31.00 | 20.93 | 13.14 | 22.55 |
| Other line items | ||||||||
Quick Ratio |
— | 8.18 | 6.63 | 32.81 | 13.65 | 10.82 | 6.03 | 13.29 |
Depreciation/Fixed assets |
— | — | 0.10 | 0.21 | 0.06 | 0.51 | 1.04 | 1.25 |
Cash ROIC |
— | (6.37%) | (19.80%) | (9.17%) | (12.36%) | (28.79%) | (24.98%) | (11.96%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.15) | (0.47) | (0.55) | (0.43) | (0.67) | (0.37) | (0.39) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.28 | 0.28 | 0.51 | 0.69 | — | — | — |
Average Payables |
— | — | — | 0.43 | 0.74 | 0.88 | 0.52 | 1.29 |
Average Assets |
— | 11.98 | 21.98 | 33.67 | 41.29 | 29.71 | 20.11 | 26.06 |
Average Common Equity |
— | 19.85 | 19.23 | 31.64 | 39.39 | 27.46 | 17.82 | 19.12 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates